These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 19353351

  • 1. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M, Agusti AG, Barnes NC.
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [Abstract] [Full Text] [Related]

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 3. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 22; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 4. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 22; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J.
    Respir Res; 2009 Jun 30; 10(1):59. PubMed ID: 19566934
    [Abstract] [Full Text] [Related]

  • 6. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan 30; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 7. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE.
    COPD; 2009 Feb 30; 6(1):1-3. PubMed ID: 19229702
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 30; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 30; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
    Respir Med; 2009 Jan 30; 103(1):12-21. PubMed ID: 19010652
    [Abstract] [Full Text] [Related]

  • 11. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 30; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 12. Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.
    Keating GM, McCormack PL.
    Drugs; 2007 Jul 30; 67(16):2383-405. PubMed ID: 17983257
    [Abstract] [Full Text] [Related]

  • 13. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec 30; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 14. Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma.
    Hoshino M, Handa H, Miyazawa T.
    Allergol Int; 2009 Sep 30; 58(3):357-63. PubMed ID: 19454840
    [Abstract] [Full Text] [Related]

  • 15. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP.
    Am J Med; 2006 Oct 30; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [Abstract] [Full Text] [Related]

  • 16. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 30; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 17. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J.
    Eur Respir J; 2009 Sep 30; 34(3):641-7. PubMed ID: 19443528
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May 30; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 19. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 May 30; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 20. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.
    Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B.
    Chest; 2009 Dec 30; 136(6):1456-1465. PubMed ID: 19581353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.